chemie.pr-ots.at: das APA-OTS-Portal für multimediale Presseaussendungen
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel.Patients Out to One Year = 14.05.2008 / 18:46
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
14.05.2008 19:40:05
Abbott Laboratories: Barcelona, Spain (ots/PRNewswire) - - Data from SPIRIT II and III Clinical Trials Also Show Improvement in Vessel Renarrowing with XIENCE V Compared to TAXUS in Patients with Small Vessels Data presented today from an independent pooled ...
Lesen Sie hier weiter... |
Drucken |
PDF
Ähnliche Artikel
- XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
- FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
- Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
- Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System
- Abbott Recognized on Dow Jones Sustainability Index (DJSI) for Fourth Consecutive Year
- Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First'Real World, All Comers' Clinical Study
- Coversyl(R) Protects Hypertensive Patients Against New-Onset Diabetes
- Abbott Study Shows Investigational Heat-Stable Norvir(R) Tablet Provides Similar Drug Levels to Current Norvir Capsule
- Wissenschaftler von Abbott stellen neuen Ansatz zur Behandlung der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung vor
- Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
Abbott Laboratories Pressemitteilungen News | PresseEcho.de
Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms
PRA International spricht während des europäischen Kongresses ...
XIENCE(TM) V Drug Eluting Stent XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Presseportal.de - Abbott Laboratories
Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year for XIENCE(TM) V Drug Eluting Stent in France
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse ...
Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year XIENCE V Compared to TAXUS in Patients with Small